GPX4 and non-small cell lung carcinoma: For example, enhanced ferroptosis as a result of GPx4 inhibition increases the sensitivity of colorectal cancer to oxaliplatin, non-small-cell lung cancer to lapatinib, and Epstein–Barr-virus-infected nasopharyngeal carcinoma to platinum [153,154,155].